Search

Primidone

[L11112] Primidone was developed by J Yule Bogue and H C Carrington in 1949.[A189522] Primidone was granted FDA Approval on 8 March 1954.[L11112] … Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures.

Alpelisib

[L6652] In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.[L41384] … Alpelisib was granted FDA approval on 24 May 2019.

Icosapent ethyl

FDA approved on July 26, 2012. … It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.

Elivaldogene autotemcel

[L40298] In September 2022, Skysona was approved by the FDA.[L43247] … It was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder.

Recombinant stabilized RSV B prefusion F antigen

[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … of an adjuvant.

Bentiromide

Bentiromide is currently not available in the U.S. or Canada. … Bentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy.

Zinc ascorbate

Agomelatine

Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. … In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011.

Apomorphine

It was first synthesized in 1845 and first used in Parkinson's disease in 1884. … [A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919]

Linaclotide

Linaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively. … Linaclotide is a synthetic 14-amino acid cyclic peptide [A260271] and first-in-class guanylate cyclase-C (G-CC) agonist.